About

Partnering

• We are committed to building sustainable relationships across the scientific and business community to establish value-creating collaborations and partnerships
• Our partnership with world leading clinical centres, Mt. Sinai and HCG enables us to validate our pipeline and streamline our efforts in building a portfolio of immuno oncotherapeutics
• We are actively seeking opportunities to partner development of bispecifics/ CART/ CAR-NK molecules using our proprietary antibody discovery platforms to fast track development
• We offer flexible- full service bespoke services for analytical and process development
• We have licensed our biologic product for the treatment of breast cancer and are in dialogue with industry leaders for early stage licensing of our lead asset, ZM 008

For information on partnering and collaborations, please write to kavithaiyer.rodrigues@zumutor.com

–

Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immunooncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery

–

On 12 November, 2019 Zumutor Biologics and Prof. Vijay Kuchroo Laboratory (Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital Ann Romney Center for Neurologic Diseases) have inked an agreement to discover unique human monoclonal antibodies against a novel cytokine identified by Kuchroo Laboratory. Zumutor will use its proprietary antibody discovery platform INABLR® to identify novel antibody clones against the cytokine

–

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors